WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Co
Dec 22, 2009
December 22, 2009 – Shanghai, China – WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected for the Deloitte Technology Fast 500 Asia Pacific 2009 List, the only company in China to receive this award for the past six years. The Deloitte program recognizes technology companies in the Asia Pacific region that have achieved the highest rates of revenue growth during the preceding three years.
"We are pleased and honored to receive this award again," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "It speaks to the soundness of our long-term business model and the effort, talent, and customer focus of our scientists. At WuXi PharmaTech, we continue to expand our pharmaceutical R&D service capabilities and capacity to best serve our customers and to sustain long-term revenue growth."
About WuXi AppTec and WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices. Please visit: http://www.wuxiapptec.com.